About Us

VivoSense develops and validates real-world digital clinical measures and provides end-to-end services and solutions for their delivery in regulated clinical trials.

VivoSense is dedicated to improving patient clinical research and care. Our hypothesis-driven framework provides analytical and clinical validation leading to FDA approval. Delivering novel digital biomarkers from wearable sensor data, which constitute primary and secondary clinical endpoints in regulated international pharmaceutical trials.

Our Mission

Advance Knowledge

We believe the study of human health in real-world, everyday environments is necessary to advance knowledge and discovery.

Advance Knowledge

Body-Worn Monitoring

We make this possible by providing customized body-worn monitoring and analysis solutions rooted in scientific foundations.

Body-Worn Monitoring

Accurate Data Analysis

We enable the world’s best researchers to obtain the highest quality, real-world data and analyze it appropriately and accurately.

Accurate Data Analysis

The VivoSense Story

Since 2010 VivoSense has been helping clinical researchers analyze and interpret wearable sensor data to improve patient research and care.

VivoSense is innovating within the pharmaceutical clinical trial industry by developing new digital biomarkers using their proprietary VivoSense® software. The platform is designed to deliver real-world digital clinical measures from wearable sensors, which will help to advance patient-focused drug development and precision medicine for patients with cancer, Alzheimer’s, rare disease and other therapeutic indications. The technology allows rigorous interpretation of subtle shifts in human physiology through customized, body-worn monitoring and analysis solutions rooted in scientific foundations.

The company is working to realize the potential of novel measures and technologies in regulatory and medical decision making to leverage real-world data at scale, bringing life-saving treatments to the patients who need them most.

“Measures that are trusted and valued by all stakeholders are the foundation on which all other innovation in digital health must be based." ~ Dudley Tabakin, chief executive officer of VivoSense

VivoSense closed a $25 Series A financing in March of 2022. The financing will accelerate the development of novel digital biomarkers and improve digital clinical outcome assessments (COAs). VivoSense will also use this financing to expand and refine its informatics platform for data analysis from wearable and connected technologies to deliver validated digital COAs for life science research.

Board of Directors

Dudley Tabakin <i class=" title="Dudley Tabakin " >

Dudley is CEO and co-founder of VivoSense and a fervent believer in “good data” over “big data” in the development of digital clinical measures from wearable sensor technology. He has a background in sports and gait biomechanics and more than 10 years experience in wearable sensor data analytics.

Tanja Dowe <i class=" title="Tanja Dowe " >

Tanja is the CEO of Debiopharm Innovation Fund, an evergreen fund investing in digital health companies that transform patient journeys and pharmaceutical R&D. Prior to joining Debiopharm, Tanja was the Managing Partner of Innomedica Ltd, a boutique strategy and transaction consulting company in life sciences, and a founder/CEO of a market research agency BioSolutions INT.

Chris Garabedian <i class=" title="Chris Garabedian " >

Chris founded Xontogeny in June of 2016 to support multiple promising technologies from early development through clinical proof of concept. In 2017, Chris joined Perceptive Advisors to develop their Venture Fund strategy and is Portfolio Manager of the Perceptive Xontogeny Ventures Fund which supports early stage companies with Series A investments across biotech, medtech and healthtech.

Lance Myers <i class=" title="Lance Myers " >

Lance has 20+ years experience in digital health and has held multiple executive leadership positions over the course of his career. He was the Founding CEO of VivoSense from 2010 - 2014. Since 2017 he has served as the Head of Data Science at Verily Life Sciences and also leads a cardiovascular innovations business unit.

Core Values

VivoSense - About Us
  • Better Outcome for Patients: VivoSense is committed to the development of better medicines and medical interventions for improved patient outcomes.
  • Scientific Integrity: Guided by scientific principles, applying leading-edge methodologies with accuracy, academic transparency within the regulated framework required by our industry.
  • Customer-Centric: VivoSense never tells the customer anything but the scientific truth, never promising what cannot be delivered.
  • Business Friendly: VivoSense values partnerships in business and is always a good corporate partner.
  • Diversity and Inclusion: VivoSense is committed to diversity and inclusion, where every voice is heard and the best-reasoned facts are those acted upon.
  • Environmental Responsibility: VivoSense strives for a minimal environmental impact, printing documents and traveling for business only when necessary.
  • Family Values: VivoSense recognizes the balance in work and family and provides for a flexible schedule, encouraging telecommuting whenever possible and minimizing the need for commuting at all times.